Latest Neurology News

Page 1 of 8
Saluda Medical has received CE certification for its EVA™ Sensing Technology, enabling commercialisation in Europe and recognition in Australia following prior FDA approval. This milestone sets the stage for a broader rollout of its personalised spinal cord stimulation therapy in early 2026.
Ada Torres
Ada Torres
22 Dec 2025
TrivarX has received $3.5 million in second-tranche placement funding, enabling advancement of its innovative Stabl-Im technology for early, non-invasive brain tumour detection. The funding supports manufacturing scale-up and regulatory preparations ahead of a planned Phase 1 clinical trial in 2026.
Ada Torres
Ada Torres
22 Dec 2025
Neuren Pharmaceuticals has secured Health Canada approval to expand its pivotal Phase 3 trial of NNZ-2591 for Phelan-McDermid syndrome into Canadian sites, complementing ongoing US enrolment.
Ada Torres
Ada Torres
22 Dec 2025
Neurotech International has locked in $4 million through a share placement to advance its promising paediatric neurological drug, NTI164. The raise, supported by both new and existing investors including company directors, aims to fund critical clinical and regulatory milestones.
Ada Torres
Ada Torres
17 Dec 2025
Epiminder Limited has settled a $15.77 million tax liability with the ATO related to historical R&D claims, freeing up $4.23 million from IPO proceeds for working capital.
Ada Torres
Ada Torres
17 Dec 2025
Neuren Pharmaceuticals’ partner Acadia secures FDA approval for DAYBUE STIX, a new powder formulation of trofinetide offering greater flexibility for Rett syndrome patients. This milestone expands treatment options and sets the stage for increased royalty revenue in 2026.
Victor Sage
Victor Sage
15 Dec 2025
Argenica Therapeutics’ AI-powered reanalysis of its Phase 2 trial reveals significant efficacy of ARG-007 in severe acute ischemic stroke patients, highlighting improved functional outcomes and reduced brain damage.
Ada Torres
Ada Torres
11 Dec 2025
Cogstate Ltd reports a near doubling in sales contracts for the first half of 2026 but warns of timing-related revenue deferrals that will temper short-term earnings. Despite this, management remains optimistic about medium- and long-term growth prospects.
Ada Torres
Ada Torres
10 Dec 2025
Resonance Health has revealed ambitious growth plans at its 2025 AGM, projecting revenue to nearly quadruple by FY26 while maintaining positive EBITDA guidance. The company is broadening its global footprint and diversifying its clinical trial services across multiple therapeutic areas.
Ada Torres
Ada Torres
13 Nov 2025
Neurotech International has received a $4.73 million R&D tax incentive refund, reinforcing its clinical development efforts in paediatric neurological disorders. The funds will support ongoing trials and working capital needs.
Ada Torres
Ada Torres
12 Nov 2025
Invex Therapeutics has appointed two new non-executive directors and joint company secretaries, signaling a refreshed governance structure alongside a change of company address.
Ada Torres
Ada Torres
10 Nov 2025
EMVision Medical Devices has successfully closed an oversubscribed Share Purchase Plan, raising $2 million and bringing total recent capital to $14 million. This funding positions the company to advance pivotal clinical trials and regulatory milestones for its innovative neurodiagnostic devices.
Ada Torres
Ada Torres
31 Oct 2025